REGENERON PHARMACEUTICALS (REGN) Stock Analyst Ratings
USA - NASDAQ:REGN - US75886F1075 - Common Stock
577.95 USD
+2.26 (+0.39%)
578 USD
+0.05 (+0.01%)
ChartMill assigns a Buy % Consensus number of 81% to REGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 744.96. This target is 28.9% above the current price.
REGN was analyzed by 34 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about REGN.
In the previous month the buy percentage consensus was at a similar level.
REGN was analyzed by 34 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-10-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-10-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-27 | Bernstein | Maintains | Outperform -> Outperform |
| 2025-08-27 | Jefferies | Maintains | Buy -> Buy |
| 2025-08-11 | Truist Securities | Maintains | Buy -> Buy |
| 2025-08-04 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-04 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-08-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-08-04 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-07-11 | UBS | Maintains | Neutral -> Neutral |
| 2025-07-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-06-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-06-05 | UBS | Maintains | Neutral -> Neutral |
| 2025-06-02 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-06-02 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-06-02 | Citigroup | Maintains | Buy -> Buy |
| 2025-05-30 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-05-27 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-14 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-05-01 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-30 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-04-30 | UBS | Maintains | Neutral -> Neutral |
| 2025-04-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-04-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-30 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-30 | Baird | Maintains | Neutral -> Neutral |
| 2025-04-30 | Goldman Sachs | Maintains | Buy -> Buy |
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the average price target for REGENERON PHARMACEUTICALS stock?
34 analysts have analysed REGN and the average price target is 744.96 USD. This implies a price increase of 28.9% is expected in the next year compared to the current price of 577.95.
Can you provide the consensus rating for REGENERON PHARMACEUTICALS stock?
The consensus rating for REGENERON PHARMACEUTICALS (REGN) is 81.1765 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for REGN stock?
The number of analysts covering REGENERON PHARMACEUTICALS (REGN) is 34.